ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
9.79
-0.10 (-1.01%)
Jun 26, 2026, 4:00 PM EDT - Market closed

Company Description

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.

It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E.

coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E.

coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation.

In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.

It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

ImmuCell Corporation
ImmuCell logo
Country United States
Founded 1982
IPO Date Apr 30, 1987
Industry Biotechnology
Sector Healthcare
Employees 73
CEO Paul F. Te Boekhorst

Contact Details

Address:
56 Evergreen Drive
Portland, Maine 04103
United States
Phone 207 878 2770
Website immucell.com

Stock Details

Ticker Symbol ICCC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000811641
CUSIP Number 452525306
ISIN Number US4525253062
Employer ID 01-0382980
SIC Code 2835

Key Executives

Name Position
Paul F. Olivier Te Boekhorst President, Chief Executive Officer and Director
Bobbi Jo Brockmann Senior Vice President of Sales and Marketing
Elizabeth S. Toothaker Director of Finance and Administration and Controller
A. Gustavo Scaffa Senior Director of Quality
John W. Zinckgraf Director of Product Development

Latest SEC Filings

Date Type Title
Jun 17, 2026 8-K Current Report
Jun 10, 2026 8-K Current Report
May 14, 2026 8-K Current Report
May 14, 2026 10-Q Quarterly Report
May 13, 2026 10-K/A [Amend] Annual report
May 8, 2026 8-K Current Report
Apr 24, 2026 DEF 14A Other definitive proxy statements
Apr 14, 2026 PRE 14A Other preliminary proxy statements
Apr 14, 2026 8-K Current Report
Apr 8, 2026 8-K Current Report